-
Analyst Opinions
Digging Deeper into Sustainability – Key Disruptive Forces in Mining (Vol.3)
Disruptive Forces in Mining Report Overview The demand for cleaner and more sustainable energy solutions such as flow batteries is rising owing to growing ESG pressure. Flow batteries have emerged as a promising technology that can contribute to a more reliable and environmentally friendly energy landscape. Leading players as well as startups are investing in developing sustainable solutions. For instance, the new kind of sodium batteries, being developed by startups such as Finland-based Broadbit and India-based AR4 Tech offer much...
-
Company Insights
Expedia Group Inc. – Digital Transformation Strategies
Expedia Digital Transformation Strategies Overview Expedia Group, Inc. (Expedia Group) is implementing innovative technologies to enhance its operations and provide better customer service. AI, cloud, digital payments, and virtual and augmented reality are among the key technologies under focus for the company. The annual ICT spending of Expedia is estimated at $729.6 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, networks, and communications from vendors. Expedia is a US-based online travel company operating...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QBS-10072S in Brain Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. QBS-10072S in Brain Cancer Drug Details: QBS-10072S is under development for the treatment of solid...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Multiple Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RG-6035 in Multiple SclerosisDrug Details:RG-6035 is under development for the treatment of relapsing multiple sclerosis and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tominersen in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tominersen in Huntington Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tominersen in Huntington DiseaseDrug Details:Tominersen (RG-6042) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Autosynvax in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Autosynvax in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AutoSynVax in Solid Tumor Drug Details:AutoSynVax is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Poly-ICLC in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Poly-ICLC in Non-Small Cell Lung Cancer Drug Details: Poly-ICLC...
-
Thematic Analysis
Cryptocurrencies in Travel and Tourism – Thematic Intelligence
Explore trends and insights from the following data in our ‘Cryptocurrencies in Travel and Tourism’ thematic report: This thematic report provides an overview of the impact cryptocurrencies have on the travel sector and seeks to understand some of the contributory factors. The key trends within this theme are split into three categories: technology trends, macroeconomic trends, and regulatory trends. Several case studies are included to analyze the multiple ways countries and companies have responded to the impact of this theme’s...